Biogen Ma Inc.

Biogen Idec Ma Inc.

Biogen, Incorporated

Margot Brickelmaier

Paula S Hochman

Adrian Whitty

Laura Runkel

Blake Pepinsky

Alexey Alexandrovich Lugovskoy

Leonid Gorelik

An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Polymer conjugates of interferon beta-1A and uses

The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.

Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)

A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.

Interferon-beta-1a-immunoglobulin fusion proteins and uses

Polymer conjugates of interferon beta-1a and uses

Interferon-beta fusion proteins and uses

Growing community of inventors

Boxford, MA, United States of America

Margot Brickelmaier